More than 75% of emergency physicians will be named in a malpractice suit over the course of their careers. When a case is brought to trial, it is the chart that will be the primary source of information, not the faded memories of an encounter that happened years in the past. Being mindful of all 3 audiences that the chart is generated for and developing techniques to adequately address all 3 should be the focus of the clinician when documenting a patient encounter.
View Article and Find Full Text PDFAm J Infect Control
December 2023
Objectives: We designed this study to test whether clazakizumab, a direct interleukin-6 inhibitor, benefits patients hospitalized with severe or critical COVID-19 disease accompanied by hyperinflammation.
Design: Multicenter, randomized, double-blinded, placebo-controlled, seamless phase II/III trial.
Setting: Five U.
Background: Previous single-center studies suggest that exposure to a room previously occupied by a patient with CDI may increase the risk of CDI in subsequent patients. We evaluated the risk of previous room occupant on CDI risk across 5 adult hospitals.
Methods: This is a non-concurrent cohort study of adult inpatients admitted to 5 hospitals.
Objective: To evaluate the role of procalcitonin (PCT) results in antibiotic decisions for COVID-19 patients at hospital presentation.
Design, Setting, And Participants: Multicenter retrospective observational study of patients ≥18 years hospitalized due to COVID-19 at the Johns Hopkins Health system. Patients who were transferred from another facility with >24 hours stay and patients who died within 48 hours of hospitalization were excluded.